Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers

Schwartz, Myron; Dvorchik, Igor; Roayaie, Sasan; Fiel, M. Isabel; Finkelstein, S. D.; Marsh, J. Wallis; Martignetti, John A.; Llovet, Josep M.

doi:10.1016/j.jhep.2008.03.032

Cited by 77 publications

(58 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinicopathological variables including tumor size, tumor grade, microscopic/macroscopic vascular invasion, and alpha-fetoprotein, were important prognostic factors for tumor recurrence in HCC patients post-LT [16][17][18]. However, the current predictive model based on clinicopathological characteristics is still unsatisfactory and molecular-based tumor staging is critical for individualized diagnosis and therapy [32,33]. Our findings demonstrate MACC1 or combination of MACC1/FAK as a complement to predict the prognosis of HCC following LT.…”

Section: Discussionmentioning

confidence: 70%

Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation

Yang¹,

Zhang²,

Wu³

et al. 2012

Journal of the American College of Surgeons

View full text Add to dashboard Cite

Background: Metastasis-associated in colon cancer-1 (MACC1) acts as a promoter of tumor metastasis; however, the predictive value of MACC1 for hepatocellular carcinoma (HCC) after liver transplantation (LT) remains unclear. Methods: We examined the expression of MACC1 and its target genes MET and FAK by quantitative PCR in 160 patients with HCC that was undergone LT. Results: The patients with MACC1high or FAK high in HCCs showed a significantly shorter overall survival and higher cumulative recurrence rates after liver transplantation (LT), compared with MACC1 low or FAK low group. Multivariate analysis indicated that MACC1 alone or combination of MACC1/FAK was an independent prognostic factor for overall survival and cumulative recurrence. Conclusions: MACC1 or combination of MACC1/FAK could serve as a novel biomarker in predicting the prognosis of HCC after LT.

show abstract

Section: Discussionmentioning

confidence: 70%

Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation

Yang¹,

Zhang²,

Wu³

et al. 2012

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

“…However, tumor number and size was very limited to predict important pathologic variables including microvascular invasion and differentiation. Recently, biomarkers, response to transarterial chemoembolization (TACE), gene-expression profile, PET/CT, AFP, and PIVKA-II, have been used for the assessment of tumor aggressiveness (5,(10)(11)(12)(34)(35)(36)(37)(38)(39).…”

Section: Predicting Pathologic Resultsmentioning

confidence: 99%

Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma

Lee

Kim

2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

Living donor liver transplantation (LDLT) becomes an important option for treatment for patients with hepatocellular carcinoma (HCC). With the advance of imaging modalities such as computed tomography (CT) and magnetic resonance image (MRI), preoperative staging and diagnosis for HCC was improved in LDLT. However, morphological characteristics based on the tumor number and size do not represent the tumor pathology and prognosis clearly. Therefore, many criteria using various markers have been reported, but still have limitation to predict the pathology and prognosis. Recently, 18F-fluorodeoxyglucose-positron emission tomography/CT (18F-FDG PET/CT) was introduced to havethe usefulness for detection of extrahepatic metastases and prediction of post-transplant prognosis in liver transplantation (LT). Furthermore, the hybrid concept with both biologic activity using PET/CT and morphologic tumor characteristics using CT and MRI was reported to be selection criteria for the patient with HCC waiting LDLT. We will discuss the role of 18F-FDG PET/CT in LDLT as various aspects including tumor detection, pathology prediction, prognosis prediction, and possibility of selecting criteria.

show abstract

“…An expansion of the Milan criteria to "up-to-seven" criteria (the sum of the size of the largest tumor and the number of tumors in patients without microvascular invasion) was proposed [23] and externally validated in an independent series [26] , but requires larger prospective validation studies [3] . Although listing criteria for LTx currently depend on tumor number and size, the use of molecular markers and gene signatures for determining tumor behavior are under development [27] . The presence of vascular invasion, high AFP level, and transplant waiting time of more than 6 mo, are considered accurate predictive factors for poor survival and recurrence risk.…”

Section: Liver Transplantationmentioning

confidence: 99%

Recent advances in multidisciplinary management of hepatocellular carcinoma

Gomaa¹

2015

WJH

View full text Add to dashboard Cite

Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers

Abstract: Analysis of allelic imbalance of 9 microsatellites identifies a subgroup of patients who, despite having hepatocellular carcinoma beyond Milan criteria, have a low risk of posttransplant recurrence.

Cited by 77 publications

References 30 publications

Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation

Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation

Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma

Recent advances in multidisciplinary management of hepatocellular carcinoma

Contact Info

Product

Resources

About